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Introduction: The renin-angiotensin system plays a major role in the
pathogenesis of metabolic syndrome. The objective of this study was to examine
the effects of aliskiren, a direct renin inhibitor, on the metabolic syndrome of
fructose-fed rats. 
Material and methods: Male Sprague-Dawley rats were divided into 4 groups 
(n = 6 for each group). Group Con: rats were fed a standard chow diet for 
8 weeks, group Fru: rats were fed a high fructose diet (60% fructose) for 8 weeks,
group FruA: rats were fed a high fructose diet and were co-infused with aliskiren
(100 mg/kg/day), and group FruB: rats were treated as group Fru, but aliskiren
was administered 4 weeks later. Systolic blood pressure (SBP), homeostasis
model assessment-insulin resistance (HOMA-IR), and blood profiles were
measured. 
Results: By the end of week 4 and 8 of a high fructose diet, SBP had increased
significantly from 111 ±5 to 142 ±4 and 139 ±5 mmHg (p < 0.05), respectively.
A high fructose diet significantly increased HOMA-IR from baseline (6.15 ±1.59)
to 21.25 ±2.08 and 21.28 ±3.1 (p < 0.05) at week 4 and 8, respectively, and
significantly induced metabolic syndrome. Concurrent aliskiren treatment
prevented the development of hypertension and metabolic syndrome in fructose-
fed rats. When fructose-induced hypertension was established, subsequent
aliskiren treatment for 4 weeks reversed the elevated SBP and ameliorated
metabolic syndrome. There were no significant differences in food, water intake,
urine flow or body weight gain among groups. 
Conclusions: Aliskiren not only prevents but also ameliorates metabolic syndrome
in fructose-fed rats.
Key words: aliskiren, direct renin inhibitor, fructose, hypertension, metabolic
syndrome.
Introduction
Metabolic syndrome, a worldwide issue, has been regarded as the
existing development of overall and central obesity, impaired glucose
tolerance, dyslipidaemia (combination of low levels of high-density
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lipoprotein cholesterol and high levels of
triglycerides), and hypertension [1, 2]. Similarly,
emerging data suggest that experimental fructose
consumption tends to produce some of the changes
associated with metabolic syndrome even without
increasing body weight [3]. The detrimental
metabolic processes related to fructose con  -
sumption seem unlimited to obesity-pathway
mechanisms [3]. Therefore, this animal model of
fructose-fed rats is popularly utilized to study the
metabolic disturbances and hypertension, inde  -
pendent of obesity or genetic contributions.
It is well recognized that the renin-angiotensin
system (RAS) plays an important physiological role
in the control of body fluid and blood pressure
homeostasis, through its effects on cardiovascular,
renal and neural functions [4]. Our previous studies
demonstrated that angiotensin (Ang) converting
enzyme (ACE) inhibitor and Ang II type 1 receptor
blockers (ARB) reduce blood pressure and improve
insulin sensitivity in hyperinsulinaemia-induced
hypertensive rats [5, 6]. These results are consistent
with reports by others [7, 8]. For example, recent
clinical trials demonstrated that the use of an ACE
inhibitor and ARB significantly reduced the risk of
developing diabetes compared with other classes
of antihypertensive agents [7, 8], indicating that
inhibition of the RAS may contribute to the
improvement of insulin resistance. Similarly,
Aliskiren, a renin inhibitor, has been demonstrated
to reduce blood pressure in spontaneously
hypertensive rats [9], essential hypertensive
patients and type 2 diabetes with hypertension 
[10, 11]. Further, the effects of aliskiren on the
metabolic syndrome are currently under investi  -
gation. Therefore, we undertook this study to
evaluate the effects of aliskiren on the metabolic
syndrome in rats fed with a high fructose diet.
Material and methods
Animals 
Male Sprague-Dawley rats initially weighing
200 g to 230 g were used for the experiments. 
All experimental procedures were carried out in
accordance with prior approval of the Institutional
Animal Care and Use Committee of Tzu Chi
University (TCU 98-05). Rats were kept in a room
with air maintained at a temperature of 24-27°C,
humidity of 50-80% and a 12-h light/dark cycle, and
had access to tap water ad libitum throughout the
experiments.
The standard chow diet was composed of 50%
starch, 21% protein, 4% fat, 4.5% cellulose, and
standard vitamins and mineral mix. The high
fructose diet (Harlan Teklad, Madison, WI) was
composed of 60% fructose, 21% protein, 5% fat, 8%
cellulose, and standard vitamins and mineral mix.
Experimental protocols 
After a control period of 1 week, rats were
divided into 4 groups (n = 6 for each group). Group
Con: rats were fed a standard chow diet for 8 weeks
and served as the control group, group Fru: rats
were fed a high fructose diet for 8 weeks, group
FruA: rats were fed a high fructose diet and were
co-infused with aliskiren (100 mg/kg per day, a kind
gift of Novartis Pharmaceuticals, Basel, Switzerland)
via a subcutaneous osmotic minipump, and group
FruB: rats were treated as group Fru, but aliskiren
(100 mg/kg per day) was administered 4 weeks
later. The first day of fructose feeding was
recognized as day 1. 
Body weight was measured twice a week. The
systolic blood pressure (SBP) was measured twice
a week by the tail-cuff method. Blood samples 
(1 ml) for glucose, insulin, triglycerides, and total
cholesterol were taken after 12 h of fasting at 
day 0, midpoint (day 28), and at the end of the
study (day 56) from the femoral artery under
sodium pentobarbital anaesthesia (40 mg/kg, IP).
Plasma was separated, divided into aliquots, and
frozen until analysis. 
In order to assess insulin resistance of animals,
homeostasis model assessment-insulin resistance
(HOMA-IR) was determined at day 0, day 28, and
day 56 of fructose treatment.
Measurements for systolic blood pressure
Rats were removed from the animal room and
were taken to the laboratory at 8 AM; they were
allowed free access to water and were kept in
a quiet area before SBP was measured at 9 AM. The
tail-cuff method without heating was used to
measure SBP with the use of a programmed
electrosphygmomanometer (MK-2000ST, Muro  -
machi, Tokyo, Japan) as described previously [5, 6].
The mean of 6 consecutive readings was used as
the measurement of SBP of each rat for that day,
and SBP was determined twice a week during the
control (1 week) and experimental (8 weeks)
periods.
Osmotic minipump installation 
The osmotic minipump installation was done as
in our previous studies [5, 6]. In brief, when aliskiren
was administered to rats, an osmotic minipump
(No. 2002, 14 days of active life, Alza Corp) was filled
with the agent, which was dissolved in normal
saline, and was implanted subcutaneously in rats
under brief anaesthesia with ketamine (60 mg/kg,
IP) and xylazine (7.5 mg/kg, IP). Aqueous penicillin
(5000 U/kg SC) was administered immediately after
minipump implantation. At the end of the life of
the minipump, a new minipump was implanted and
the used one removed. The residual volume in each
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minipump removed was carefully examined to




Insulin resistance was assessed via HOMA-IR,
and was determined at day 0, day 28, and day 56.
HOMA-IR was calculated using this formula:
[plasma glucose (mmol/l) × insulin (mU/ml)]/22.5.
Laboratory measurements 
The blood samples were immediately centrifuged
at 4000 g at 4°C for 10 min. The plasma samples
were separated and subjected to immediate assays
of glucose, insulin, triglycerides and total
cholesterol. Plasma levels of glucose, triglycerides
(TG) and total cholesterol were measured with
a COBAS Integra 800 analyser (Roche Diagnostics,
USA). Plasma insulin was measured by automated
chemiluminescence immunoassay via an ADVIA
Centaur analyser (Bayer, Germany).
Statistical analysis 
All results were presented as mean ± SD. Experi  -
mental data over time were analysed by two-way
analysis of variance (ANOVA) (the first factor being
the treatment group and the second the time
period) for comparison between groups. When
a significant effect was detected by ANOVA, the
Newman-Keuls test was used to establish which
difference between means reached statistical
significance. Student's t-test for unpaired data was
also performed when appropriate. Value of p < 0.05
was considered statistically significant.
Results
Aliskiren prevents and reduces the rise of SBP
in fructose-fed rats
The changes in SBP of control rats and fructose-
fed rats with or without aliskiren treatment are
illustrated in Figure 1. In control rats, SBP did not
change significantly throughout the experimental
period. However, high fructose diet alone signi  -
ficantly increased the SBP from 111 ±5 mmHg during
the control period to 142 ±4 and 139 ±5 mmHg by
the end of the 4th and 8th weeks, respec  tively.
Concomitant aliskiren treatment prevented the rise
of SBP in fructose-fed rats, and the levels were not
significantly different from those of control rats at
each corresponding time point. When fructose-
induced hypertension had been established (from
112 ±4 mmHg to 141 ±3 mmHg, p < 0.05) in rats fed
fructose for 4 weeks, subsequent aliskiren
treatment for 4 weeks reversed the elevated SBP
to the control levels.
Aliskiren does not alter the food intake, water
intake, urine flow or body weight gain in
fructose-fed rats
Effects of aliskiren on food intake, water intake,
urine flow and body weight gain of fructose-fed rats
are shown in Figure 2. There were no significant
differences in food, water intakes, urine flow or
body weight gain among groups at the corres  -
ponding time periods. 
Aliskiren prohibits and ameliorates
hyperglycaemia, hyperinsulinaemia,
hypertriglyceridaemia and
hypercholesterolemia in fructose-fed rats
Table I summarizes the effects of a high fructose
diet alone and in combination with aliskiren on
plasma glucose, insulin, triglycerides and total
cholesterol. Fructose-fed rats significantly increased
plasma glucose, insulin, triglyceride and total
cholesterol compared to control rats throughout the
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Figure 1. Changes in systolic blood pressure in control
and fructose-fed rats with or without direct renin
inhibitor (aliskiren) treatment
Group Con – rats were fed standard chow diet, group Fru –
rats were fed high fructose diet, group FruA – rats were fed
high fructose diet and were co-infused with aliskiren, group
FruB – rats were treated as group Fru, but aliskiren was
administered 4 weeks later, * and ^ denote p < 0.05 vs. pre-
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interrupted the rise of plasma glucose, insulin,
triglycerides and total cholesterol in fructose-fed
rats, and the levels were not significantly different
from those of control rats at each corresponding
time point. In addition, a high fructose diet for 
4 weeks induced hyperglycaemia, hyper  insu  -
linaemia, hypertriglyceridaemia and hyper  cho  -
lesterolemia, and subsequently in combination with
aliskiren treatment for 4 weeks reversed these
elevated parameters to the control levels.
Aliskiren suppresses and improves insulin
resistance in fructose-fed rats
The effect of aliskiren on insulin resistance of
fructose-fed rats is presented in Figure 3. There
were no significant differences in HOMA-IR values
(between 6.417 ±0.99 and 6.35 ±1.25) in control rats
throughout the experiments. A high fructose diet
significantly increased HOMA-IR values from
baseline (6.15 ±1.59) to 21.25 ±2.08 and 21.28 ±3.1
(p < 0.05) at week 4 and 8, respectively, and
significantly induced metabolic syndrome.
Fructose-fed rats had significantly higher 
HOMA-IR values at day 28 and 56 (from baseline
6.15 ±1.59 to 21.25 ±2.08 and 21.28 ±3.1 at day 28
and 56, respectively, p < 0.05) than those of control
rats and pre-fructose feeding. The levels of 
HOMA-IR (between 5.98 ±1.14 and 7.05 ±0.93) in
fructose-fed rats with concomitant aliskiren
treatment were not significantly different from
those of control rats at each corresponding time
point. Furthermore, when fructose-induced higher
HOMA-IR level had been established (from 
6.2 ±0.67 to 19.97 ±3.93, p < 0.05), subsequent
treatment with aliskiren for 4 weeks inverted the
elevated HOMA-IR to the control levels (from 19.97
±3.93 to 6.37 ±0.92, p < 0.05).
Discussion
In this rat model of fructose-fed diet, we have
demonstrated that a high fructose diet elicits the
elevation of plasma glucose, insulin, triglycerides,
total cholesterol as well as SBP . These results,
consistent with reports by others [12-14], support
the view that a sustained fructose-fed diet causes
hypertensive insulin resistance in rats. Moreover,
we found that administration of aliskiren, a direct
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Figure 2. Effects of aliskiren on food intake, water intake, urine flow, and body weight gain of fructose-fed hypertensive
rats
Group Con – rats were fed standard chow diet, group Fru – rats were fed high fructose diet, group FruA – rats were fed high fructose
diet and were co-infused with aliskiren, group FruB – rats were treated as group Fru, but aliskiren was administered 4 weeks later, 
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the development of hypertension, hyperglycaemia,
hyperinsulinaemia, hypertriglyceridaemia, hyper  -
choleste  rolemia and insulin resistance, suggesting
that renin-associated mechanisms play a pivotal
role in the development of metabolic syndrome in
rats fed with a high fructose diet.
Several studies have shown that RAS plays
a cardinal role in the pathogenesis of hypertension
in fructose-fed rats [15, 16]. In this present study,
we have shown that a direct renin inhibitor can
prevent and reverse the rise of systolic blood
pressure in fructose-fed rats, and the mechanism
may involve suppressing the generation of Ang II.
The other studies also showed that elevation of
plasma Ang II and tissue Ang II type 1 receptor
played a pivotal role in the pathogenesis of
fructose-fed hypertensive rats [15, 16]. Additionally,
chronic ACE inhibitor or ARB treatment has been
shown to decrease the rise of blood pressure and
restores the activity of endothelial nitric oxide
synthase in fructose-fed rats [17, 18].
Renin is the rate-limiting step in the generation
of Ang II, and a direct renin inhibitor suppressed
the generation of Ang II. Recently, one clinical
study showed that direct renin inhibition, by
aliskiren, might be efficacious in reducing blood
pressure and improving insulin sensitivity in
hypertensive patients with metabolic syndrome
[19]. Several experimental studies have also
shown that aliskiren might improve insulin
sensitivity and protect against pancreatic injury
in animal models of obesity, type 2 diabetes or
Ren2 rats [20-23]. The mechanisms for the direct
renin inhibitor to prevent as well as reverse
insulin resistance may act through inhibition of
the production of Ang II, and down-regulation of
the local RAS in pancreatic islet tissue and
adipose tissue. Numerous studies have illustrated
that Ang II plays an important role in insulin
resistance [24-27]. For example, Ang II acting
through Ang II type 1 receptor can inhibit insulin
signalling pathways and translocation of glucose
transporter 4 in both non-diabetic and diabetic
rats, and then facilitates the development of
insulin resistance [24, 28]. In addition, Ang II may
induce the development of insulin resistance by
its vasoconstrictor actions, thus decreasing blood
flow and glucose uptake into insulin-sensitive
tissues [25]. Moreover, Ang II infusion induces
endothelial dysfunction [26], hepatic insulin
resistance and elevations in blood pressure [27].
In the present study, we have demonstrated that
a direct renin inhibitor can improve insulin
resistance in fructose hypertensive rats. This
observation is consistent with the study from Habibi
et al., who showed that renin inhibition attenuated
insulin resistance, oxidative stress and pancreatic
remodelling in the transgenic Ren2 rat [29].
Group N Day 0 Day 28 Day 56
Glucose [mmol/l]
Con 6 6.45 ±0.81 6.33 ±0.47 6.90 ±0.20
Fru 6 6.46 ±0.79 10.54 ±0.89*# 11.86 ±1.47*#
FruA 6 6.42 ±0.68 6.49 ±0.22 7.07 ±0.45
FruB 6 6.31 ±0.45 10.67 ±1.40*# 6.74 ±0.41
Insulin [pmol/l]
Con 6 161.6 ±20.8 155.6 ±19.6 148.4 ±26.7
Fru 6 153.1 ±30.0 310.0 ±32.2*# 289.6 ±22.5*#
FruA 6 150.8 ±25.6 149.0 ± 27.7 161.6 ±24.6
FruB 6 159.2 ±20.5 301.6 ±36.3*# 160.3 ±23.0
Triglycerides [mmol/l]
Con 6 1.56 ±0.09 1.60 ±0.10 1.55 ±0.08
Fru 6 1.60 ±0.15 3.13 ±0.23*# 3.34 ±0.25*#
FruA 6 1.55 ±0.12 1.59 ±0.09 1.72 ±0.21
FruB 6 1.50 ±0.09 3.15 ±0.17*# 1.68 ±0.13
Total cholesterol [mmol/l]
Con 6 2.21 ±0.31 2.27 ±0.14 2.20 ±0.13
Fru 6 2.25 ±0.17 3.24 ±0.14*# 3.30 ±0.13*#
FruA 6 2.42 ±0.15 2.38 ±0.23 2.31 ±0.15
FruB 6 2.33 ±0.11 3.16 ±0.20*# 2.42 ±0.21
Table I. Effects of high fructose diet alone and in
combination with aliskiren on plasma glucose,
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Figure 3. Effect of aliskiren on insulin resistance 
of fructose-fed rats
Group Con – rats were fed standard chow diet, group Fru –
rats were fed high fructose diet, group FruA – rats were fed
high fructose diet and were co-infused with aliskiren, group
FruB – rats were treated as group Fru, but aliskiren was
administered 4 weeks later, HOMA-IR – homeostasis model
assessment of insulin resistance, * and ^ denote p < 0.05 vs.
pre-fructose and control rats, respectively, n = 6 for each
group
Con indicates control rats with normal chow diet, Fru – fructose-fed
diet, FruA – fructose-fed diet with concurrent aliskiren administration,
FruB – fructose-fed diet and further aliskiren administration after 
4 weeks of fructose-fed diet; *p < 0.05 vs. day 0, #p < 0.05 vs. control
group
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Similarly, blockade of the effects of Ang II may
improve blood flow to insulin-sensitive tissues and
increase islet blood flow for an adequate insulin
release [30]. Several animal studies have also
demonstrated that inhibition of the RAS with an
ACE inhibitor or ARB not only prevents but also
reduces hypertension, and improves insulin resis  -
tance in a high fructose-fed animal model [25, 31].
Furthermore, interruption of the RAS via chronic
ACE inhibition or ARB reduces oxidative stress and
restores NO production in fructose hypertensive
rats [15, 17, 18], which can lead to improved insulin
signalling and resistance in pancreas and skeletal
muscle [7, 30, 32]. 
Whether or not inhibition of RAS can blunt the
rise of triglycerides in fructose-fed hypertensive rats
is still under debate. A study [33] reported that
either ACE inhibitor or ET blockade did not decrease
the hypertriglyceridaemia in fructose hypertensive
rats, although the combination of both inhibitors
significantly diminished hypertriglyceridaemia in
fructose hypertensive rats. However, another study
showed that blockade of the RAS via ACE inhibitor
or ARB could reduce hypertension and hypertri  -
glyceridaemia and improve insulin sensitivity [34].
In the present study, aliskiren not only prevented
but also reversed hypertriglyceridaemia and
hypercholesterolemia to normal levels in fructose
hypertensive rats. The mechanism of action for
aliskiren is unclear and may be due to down-
regulation of local RAS in adipose and liver tissue.
A recent study in obese mice fed with a high fat
diet demonstrated that systemic inhibition of renin
via aliskiren elicited a decline of adipose Ang I and
Ang II, visceral adiposity and plasma leptin.
Furthermore, aliskiren normalized adipose tissue
function, and allowed triglycerides to be stored in
adipocytes and not in other tissues, and improved
insulin resistance [35]. Another study showed that
ARB reduced hepatic plasminogen activator
inhibitor-1 gene expression, decreased hepatic
triglyceride accumulation, and improved insulin
resistance [36].
The limitations of this study were the small
number of animals in each group and the lack of
a vehicle-treated group. In addition, the con  cen  -
trations of local and systemic Ang II and its
correlation with the changes in study variables were
not measured.
In conclusion, the present study demonstrates
that a high fructose diet significantly induces
metabolic syndrome (hypertension, hyperglycaemia,
insulin resistance, hypertriglyceridaemia and
hypercholesterolaemia) and is independent of
changes in food and water intake, urine flow and
body weight gain. Aliskiren, a direct renin inhibitor,
not only prevents but also reverses the deve  -
lopment of metabolic syndrome in rats fed with
a high fructose diet. In future, aliskiren-related
benefits could be expanded in the clinical setting
of the metabolic syndrome. Nevertheless, this
remains to be further confirmed by clinical studies.
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